Abstract P3-10-06: Expression-Based Immune Signatures as Predictors of Neoadjuvant Targeted-/Chemo-Therapy Response: Experience From the I-Spy 2 TRIAL of ˜1000 Patients Across 10 Therapies
doi 10.1158/1538-7445.sabcs18-p3-10-06
Full Text
Open PDFAbstract
Available in full text
Date
February 15, 2019
Authors
Publisher
American Association for Cancer Research